32 results about "Mannosamine" patented technology

Disclosed are a therapeutic pharmaceutical agent for diseases associated with the decrease in the function of GNE protein, a food composition, and a food additive. The therapeutic pharmaceutical agent is characterized by comprising a compound capable of increasing the quantity of N-acetylneuraminic acid in cells. Examples of the compound to be contained in the therapeutic pharmaceutical agent include N-acetylneuraminic acid, an intermediate produced downstream from N-acetylmannosamine in an N-acetylneuraminic acid biosynthesis pathway, an N-acetylneuraminic acid derivative, an N-acetylmannosamine derivative, an N-acetylneuraminic acid-containing compound, an N-acetylneuraminic acid derivative-containing compound, an N-acetylmannosamine-containing compound, an N-acetylmannosamine derivative-containing compound, an inhibitor of a degrading enzyme for N-acetylneuraminic acid, an inhibitor of a degrading enzyme for N-acetylmannosamine, an inhibitor of a degrading enzyme for the intermediate, and others.

The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.

The invention provides a method for producing an orexin neuron by culturing a pluripotent stem cell or a neural progenitor cell in the presence of N-acetyl-D-mannosamine and optionally in the presence of at least one inhibitor selected from the group consisting of a Sirtuin 1 inhibitor and an O-linked β-N-acetylglucosamine transferase inhibitor. The invention also provides a therapeutic agent for narcolepsy or eating disorders, such as anorexia, containing N-acetyl-D-mannosamine, which is based on the induction of orexin neuron in vivo.

The invention discloses application of N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 in catalytic synthesis of N-acetylmannosamine. The N-acetylmannosamine is prepared by taking the N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 as a catalyst and taking N-acetylglucosamine as a substrate. According to the invention, the N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 is used in the preparation of the N-acetylmannosamine for the first time, and favorable effect is achieved.

The disclosure relates to methods of enhancing beneficial oral bacteria and decreasing harmful oral bacteria comprising administering oral care compositions comprising a saccharide prebiotic, e.g., selected from D-turanose, D-melezitose, D-lactitol, myoinositol, and N-acetyl-D-mannosamine; and oral care compositions for use in such methods. The disclosure also relates to methods of using prebiotic oral care compositions, methods of screening, and methods of manufacture.

A novel method for the preparation of a compound of formula (I) from an N-protected-D-mannosamine. A compound of formula (I) is a useful intermediate for the preparation of kiftnensine, a potent and selective mannosidase inhibitor. The method includes protecting the hydroxyl group at the C-6 position of an N-protected-D-mannosamine, to give a 6-O-protected-N-protected-D-mannosamine; reducing the C-1 anomeric carbon atom of the 6-O-protected-N-protected-D-mannosamine to give a 6-O-protected-N-protected-D-mannitol; protecting the four hydroxyl groups of the 6-O-protected-N-protected-D-mannitol; and removing the nitrogen atom protecting group and optionally removing the C-6 oxygen atom protecting group to give the compound of formula (I): where R<1 >and R<2 >are each independently protecting groups which, together with the oxygen atoms to which they are attached, form a 5-, 6-, 7- or 8-membered ring; and R<3 >is hydrogen or a protecting group.

The invention relates to a three-arm mannose derivative and a preparation method thereof through combination with double-click chemistry. Firstly, a three-arm terminal alkene / alkyne compound and [alpha]-D-azide mannose ([alpha]-Man-N3) are used for carrying out a CuAAC reaction between end group alkyne and azide to generate a rigid triazole group; then, the rigid triazole group and [alpha]-D-sulfydryl mannose ([alpha]-Man-SH) carry out a Thiol-ene reaction between end group alkene and the sulfydryl to generate a flexible thioether bond; and then, under an acidic condition of trifluoroacetic acid, protection of t-butyloxycarboryl is removed to obtain one series of three-arm mannose derivatives. Compared with the prior art, the invention utilizes the advantages of the click chemistry reaction to innovatively synthesize three kinds of three-arm mannose derivatives with different structures so as to be favorable for jointly utilizing RAFT polymerization in the later stage to prepare a sugar-containing polymer of which the side chain contains tri-functional mannose and perform an important guidance meaning for researching the influence of the rigidity and the flexibility of different branched chains of the polymer of which the side chain contains three-arm mannose for the biological characteristics.

Analysis of compositions that include saccharides having mannosamine residues, such as the capsular saccharide of N. meningitidis serogroup A, is facilitated by a method comprising the steps of: (i) hydrolysing polysaccharide in the sample, to give a hydrolysate; (ii) subjecting the hydrolysate to liquid chromatography; and (iii) detecting any mannosamine-6-phosphate separated in step (ii).

Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.

The invention relates to an N-azido acetyl-D-mannosamine derivative, a preparation method thereof, and application of the N-azido acetyl-D-mannosamine derivative in esterase detection, and mainly relates to the N-azido acetyl-D-mannosamine derivative disclosed in a following formula (I), the preparation method for the N-azido acetyl-D-mannosamine derivative, and the application of the N-azido acetyl-D-mannosamine derivative in the esterase detection. R1 is selected from H, F, Cl, Br, I, -OH, -NH2, -NO2, -N3, C1-6 alkyl, C1-6 alkoxy, -CO-C1-6 alkyl, -CO-NH-C1-6 alkyl, -COOC1-6 alkyl, aryl, aryl-oxygen radicals, heteroaryl, heteroaryl-oxygen radicals, heterocyclic radicals and heterocyclic radical-oxygen radicals, wherein the aryl, the aryl-oxygen radicals, the heteroaryl, the heteroaryl-oxygen radicals, the heterocyclic radicals and the heterocyclic radical-oxygen radicals are optionally substituted by any following radicals: F, Cl, Br, I, -OH, -NH2, -NO2, -N3, C1-6 alkyl and C1-6 alkoxy; R2 and R3 are the same or different and are mutually independently selected from O, S, NH and NMe; n1 and n2 are the same or different and are mutually independently selected from integers from 1 to 4; and a brake line shows a key a or a key e.

In vitro process for the proliferation or culture of conjunctive tissue cells selected from the group consisting of chondrocytes, osteoblasts, chondroprogenitor cells, osteoprogenitor cells, tenocytes and ligament cells comprising the step of contacting said cells with an aminosugar selected from the group consisting of mannosamine, N-acetylmannosamine, mannosamine salts and their mixtures. The present invention also relates to compositions which comprise the aminosugar in combination with the cells. These compositions are useful for the treatment of cartilage, bone, tendon and ligament lesions or defects, bone mass losses and osteochondral defects or lesions.

A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjugated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugar selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extends to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.

The present invention relates to the use of peracylated N-acyl-mannosamine derivatives for the preparation of a medicament for stimulating neurite growth.

The present invention relates to the use of peracylated N-acyl-mannosamine derivatives for the preparation of a medicament for stimulating neurite growth.

Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.

The invention provides an agent for treating depression, which contains N-acetyl-D-mannosamine, and a pharmaceutical composition for treating depression, which contains an effective amount of N-acetyl-D-mannosamine and a carrier acceptable as a medicament.

The present invention relates to the application of N-azidoacetyl-D-mannosamine derivatives in the detection of esterase. The present invention mainly relates to N-azidoacetyl-D-mannosamine derivatives shown in the following formula (I) and their preparation methods and applications in the detection of esterases: wherein, R 1 is selected from H, F, Cl, Br, I, -OH, -NH 2 ,-NO 2 ,-N 3 , C 1‑6 Alkyl, C 1‑6 Alkoxy, ‑CO‑C 1‑6 Alkyl, ‑CO‑NH‑C 1‑6 Alkyl, -COOC 1‑6 Alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclyl, heterocyclyloxy; said aryl, aryloxy, heteroaryl, heteroaryloxy , heterocyclyl, heterocyclyloxy are optionally substituted by the following groups: F, Cl, Br, I, -OH, -NH 2 ,-NO 2 ,-N 3 , C 1‑6 Alkyl, C 1‑6 Alkoxy; R 2 , R 3 The same or different, independently selected from O, S, NH, NMe; n 1 , n 2 The same or different, independently selected from an integer of 1-4; representing a bond or e bond.

The invention discloses an N-azidoacetyl-D-mannosamine derivative, a preparation method, and application thereof. The structure of the compound is represented by formula (I), wherein R1 is selected from O, S, NH, NMe, and -CH = CH-; R3 is selected from O, S, NH, and NMe; R2 is selected from H, F, Cl, Br, I, -OH, -NH2, C1-6 alkyl, C1-6 alkoxy, -CO-C1-6 alkyl, -CO-NH-C1-6 alkyl, -COOC1-6 alkyl, aryl, aryloxy, heteroaryl, heteroaryloxy, heterocyclic, and heterocyclic oxy; m is selected from an integer of 1-4; A is selected from a group that can be eliminated or cleaved by itself after a catalyticreduction reaction between the compound represented by formula (I) and a nitro reductase; A represents an a bond or an e bond. The invention also provides a preparation method of the compound represented by formula (I) and application thereof in the detection of nitroreductase.

The present invention relates to compositions comprising chondroitin sulphate and mannosamine or a derivative thereof. The mannosamine derivative is preferably N-acetylmannosamine. The compositions may comprise glucosamine. Said compositions are useful in the treatment or prevention of degenerative joint diseases, preferably of osteoarthritis, in the treatment or prevention of tendon or ligament diseases, disorders or injuries and of immune system diseases, preferably of rheumatoid arthritis.

The present invention relates to an N-azidoacetyl-D-mannosamine derivative and its preparation method and application. The structure of the compound is shown in general formula (I), wherein, R 1 is selected from O, S, NH, NMe, -CH=CH-; R 3 is selected from O, S, NH, NMe; R 2 is selected from H, F, Cl, Br, I, -OH, -NH 2 、C 1‑6 Alkyl, C 1‑6 Alkoxy, ‑CO‑C 1‑6 Alkyl, ‑CO‑NH‑C 1‑6 Alkyl, -COOC 1‑6 Alkyl, aryl, aryloxyl, heteroaryl, heteroaryloxyl, heterocyclyl, heteroepoxy; m is selected from an integer of 1-4; A is selected from compounds described in formula (I) and nitric acid A group that can be eliminated or cleaved by itself after the catalytic reduction reaction of the base reductase; it represents a bond or e bond. The present invention also provides a preparation method of the compound represented by formula (I) and its application in detecting nitroreductase.

The present invention relates to a recombinant protein comprising SEQ ID NO: 1 and a bacteria recognizing lectin. The present invention also relates to uses of the recombinant protein comprising detecting pathogens, removing endotoxins, determining the presence of an endotoxin or endotoxin-like material, and determining the presence of pathogen-associated molecular pattern (PAMP) comprising rhamnose-rhamnose (Rha-Rha), rhamnose-N-acetyl-mannosamine (Rha-ManNAc), N-acetyl-mannosamine-rhamnose (ManNAc-Rha), rhamnose-galatose (Rha-Gal), or galatose-rhamnose (Gal-Rha) in a sample, and use as a medicament, a disinfectant, a decontaminant, a surfactant or a diagnostic means. The present invention further relates to a method for prevention and / or treatment of conditions related to pathogen related infections in a patient in need thereof comprising: administering to said patient a pharmaceutically effective amount of composition comprising the recombinant protein, wherein the recombinant protein functions as an antagonist of PAMP comprising Rha-Rha, Rha-ManNAc, ManNAc-Rha, Rha-Gal, or Gal-Rha.

The invention discloses a preparation method and application of a novel hymexazol oxyglycoside conjugate bactericide. Galactose, mannose, glucose, mannosamine, galactosamine, glucosamine, N-acetyl-galactosamine, N-acetyl-mannosamine and acetylglucosamine are respectively conjugated with hymexazol to obtain a series of hymexazol oxyglycoside conjugates. The structural general formula of the compound is shown as I, R is hydroxyl, oxyacetyl, amino and acetamido, and R1 is hydrogen and acetyl. The conjugate disclosed by the invention is novel in structure, has good solubility and antifungal activity, and has the potential of becoming a novel green bactericide.

The invention discloses application of N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 in catalytic synthesis of N-acetylmannosamine. The N-acetylmannosamine is prepared by taking the N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 as a catalyst and taking N-acetylglucosamine as a substrate. According to the invention, the N-acetylglucosamine isomerase of which the amino acid sequence is shown as SEQ ID NO:2 is used in the preparation of the N-acetylmannosamine for the first time, and favorable effect is achieved.

This Invention discloses a method for production of N-Acetyl-D-Glucosamine and / or D-Glucosamine Salt by microbial fermentation. The method is intended to manufacture N-Acetyl-D-Glucosamine and / or D-Glucosamine Salt in higher efficiency and higher yield, by increasing the effects of N-Acetyl-D-Mannosamine Kinase.

The disclosure relates to methods of enhancing beneficial oral bacteria and decreasing harmful oral bacteria comprising administering oral care compositions comprising a saccharide prebiotic, e.g., selected from D-mannose, N-acetyl-D-mannosamine and mixtures thereof; and oral care compositions for use in such methods. The disclosure also relates to methods of using prebiotic oral care compositions, methods of screening, and methods of manufacture.

The invention discloses a detection method of enoxaparin sodium. The detection method of the enoxaparin sodium comprises the following steps of a, taking anenoxaparin sodium sample, and carrying out hydrolysis to obtain a hydrolysis solution; b, taking the hydrolysis solution, and carrying out derivatization to obtain a solution to be detected; c, adopting a high performance liquid chromatography method to detect the solution to be detected, detecting to obtain a peak area of glucosamine and mannosamine, and calculating to obtain the proportion of the glucosamine and the mannosamine. According to the detection method provided by the invention, the proportion of the glucosamine and the mannosamine is detected, so that the product quality and / or the stability of the production process can be reflected intuitively; in addition, the detection method is simple and convenient, does not need to adopt a complicated gradient elution program so as to realize accurate detection on the enoxaparin sodium, and provides a novel simple and practical method for monitoring the product quality and / or the stability of the production process of the enoxaparin sodium.